CADTH Canadian Drug Expert Committee recommendation: Baricitinib (Olumiant -- Eli Lilly Canada Inc.) indication : for use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs) : baricitinib may also be used as monotherapy in cases of intolerance to MTX.
The CADTH Canadian Drug Expert Committee (CDEC) recommends that baricitinib be reimbursed for use in combination with MTX for the treatment of adult patients with moderate to severe RA who have responded inadequately to one or more DMARDs, if the following conditions are met : Conditions for Reimbur...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
August 2019, 2019
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that baricitinib be reimbursed for use in combination with MTX for the treatment of adult patients with moderate to severe RA who have responded inadequately to one or more DMARDs, if the following conditions are met : Conditions for Reimbursement Initiation Criteria 1. Adult patients with moderately-to-severely active RA on stable doses of DMARDs who have had inadequate response or intolerance to one or more DMARDs. 2. Baricitinib should only be used in combination with MTX (alone or with other conventional DMARDs [cDMARDs]). 3. Baricitinib should not be used in combination with other biologic DMARDs (bDMARDs), including Janus kinase (JAK) inhibitors |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (8 pages) |